
    
      Study participants will receive a single booster dose of ADACEL (Tdap vaccine) or a single
      booster dose of local DT or local Td vaccine, depending on the age subgroup.

      Immunogenicity will be assessed before and 28 days post-vaccination; safety profile will be
      assessed in all subjects up to Day 35 post vaccination.
    
  